araag2/HINT huggingface dataset:
Clinical trial NCT03249740 (phase 1, status: completed)
Conditions: neovascular age-related macular degeneration
ICD codes: H35.3211, H35.3212, H35.3221, H35.3222, H35.3231, H35.3232, H35.3291
Drugs: gb-102, aflibercept
SMILES: CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Key Inclusion Criteria:

          1. Males or females of any race, ≥ 50 years of age

          2. Presence of an active CNV lesion secondary to AMD treated with at least 3 monthly
             injections of an anti-VEGF agent (aflibercept, bevacizumab, or ranibizumab)

          3. Evidence of increased vascular permeability and/or loss of visual acuity

        Key Exclusion Criteria:

          1. History, within 6 months prior to screening, of any of the following: myocardial
             infarction, any cardiac event requiring hospitalization, treatment for acute
             congestive heart failure, transient ischemic attack, or stroke

          2. Uncontrolled hypertension, diabetes mellitus, IOP, hypothyroidism, or hyperthyroidism

          3. Chronic renal disease

          4. Abnormal liver function

          5. Women who are pregnant or lactating
Clinical trial NCT03259516 (phase 1/phase 2, status: terminated)
Conditions: myelodysplastic syndromes
ICD codes: D46.9, D46.C, D46.Z
Drugs: nivolumab, azacitidine, fludarabine, cyclophosphamide, cytarabine, all trans retinoic acid, sildenafil, melphalan
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O, CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O
Reason stopped: 
    slow recruitment rate
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with myelodysplastic syndrome (MDS) (up to 20% blasts) of any risk. Patients
             with lower risk MDS (low and int-1 by IPSS) should have failed prior
             non-hypomethylating agent therapy (ie growth factors or lenalidomide). Patients with
             higher risk MDS (int-2 or high by IPSS) should have failed prior at least one therapy
             with a hypomethylating agent or Ara-C.

          -  Age 18 years or older.

          -  No severe organ dysfunction: creatinine <=2.5 x ULN; serum bilirubin <=2.5 x ULN; AST
             and ALT <=5 x ULN.

          -  Karnofsky index >=70%

          -  Females of childbearing potential must have a negative serum or urine beta human
             chorionic gonadotrophin (beta-hCG) pregnancy test result within 24 hours prior to the
             first dose of treatment and must agree to use an effective contraception to avoid
             pregnancy for 24 weeks

          -  Males who have partners of childbearing potential must agree to use an effective
             contraceptive method during the study and for 24 weeks after the last dose of
             nivolumab.

        Exclusion Criteria:

          -  Another malignancy requiring treatment at the time of inclusion

          -  History of interstitial lung disease or pneumonitis

          -  Patients with any other known concurrent severe and/or uncontrolled medical condition
             (e.g. uncontrolled diabetes; cardiovascular disease including congestive heart failure
             NYHA Class III or IV, myocardial infarction within 6 months, and poorly controlled
             hypertension; chronic renal failure; or active uncontrolled infection) which, in the
             opinion of the investigator could compromise participation in the study

          -  Active, known or suspected autoimmune disease requiring treatment at the time of
             inclusion

          -  Pregnancy or breastfeeding

          -  Patients unwilling or unable to comply with the protocol

          -  Somatic or psychiatric disorder making the patient unable to sign informed consent

          -  Prior treatment with anti-PD-1, anti-PD-L1, or anti-CTLA4 therapy
Clinical trial NCT03263533 (early phase 1, status: withdrawn)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: vorinostat oral capsule group 1, vorinostat oral capsule group 2
SMILES: ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
Reason stopped: 
    pis were unable to recruit any participants
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with DSM-5 Schizophrenia

          -  Receiving stable dose pf clozapine (≥ 300 mg per day) for at least 6 months before
             entering the study

        Exclusion Criteria:

          -  Taking specific psychotropic medications (lamotrigine and valproic acid)

          -  Current or recent (12-months) substance use or induced disorder

          -  History of significant neurological or medical disorders

          -  Intellectual disability

          -  Known contraindications to the administration of vorinostat per product labeling

          -  Women currently pregnant, planning to become pregnant, or receiving hormone therapy
             and refusing any form of birth control
Clinical trial NCT03270332 (early phase 1, status: recruiting)
Conditions: pulmonary hypertension
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: albuterol first then placebo, placebo first then albuterol
SMILES: CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  A Mean Pulmonary Artery Pressure >25mmHg, Pulmonary Vascular Resistance >3 wood/units
             and pulmonary arterial wedge pressure <15mmHg, as documented by right heart
             catheterization within the last 3 years

          -  Regular use of oral pulmonary vasodilators

        Exclusion Criteria:

          -  Presence of chronic respiratory disease (as documented by prior lung imaging and
             pulmonary function tests), cardiovascular disease (as documented by prior
             echocardiography and/or left heart catheterization), thromboembolic PAH (as documented
             by pulmonary angiography)

          -  women of childbearing potential who do not use accepted birth- control measures

          -  pregnant and breast-feeding women

          -  respiratory infection within 4 weeks of testing

          -  A systemic systolic arterial BP> 150 and/or diastolic arterial BP>100 on the
             experiment day

          -  A resting O2 saturation of < 90%

          -  Current smoking

          -  BMI >35 kg/m2 and/or a diagnosis of obstructive sleep apnea

          -  Use of inhaled or intravenous pulmonary vasodilators
Clinical trial NCT03309358 (phase 1, status: terminated)
Conditions: lung diseases, pulmonary disease, cystic fibrosis, cystic fibrosis lung, cystic fibrosis pulmonary exacerbation, cystic fibrosis with exacerbation, respiratory tract disease, pulmonary inflammation, multi-antibiotic resistance, antibiotic resistant infection, lung infection, lung infection pseudomonal, lung; infection, atypical mycobacterium, burkholderia infections, burkholderia cepacia infection, lung inflammation
ICD codes: J84.115, M05.10, M05.111, M05.112, M05.119, M05.121, M05.122, I27.9, J84.9, I28.9, J44.9, I27.22, J44.1, J44.0, E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4, T86.812, T86.33, B67.1, K94.02, K94.12, K94.22, K94.32, N99.511, A02.9, A31.0, H01.9, H30.93, H05.00, H30.003, H30.013, H30.033, H30.103
Drugs: inhaled snsp113, inhaled placebo
SMILES: CC1=CC(O)=CC(C)=C1Cl
Reason stopped: 
    successful completion of part a. company decision to end early.
  
Eligibility criteria:

        Inclusion Criteria:

        Part A

          -  Healthy male adults ≥18 and ≤50 years of age at screening.

          -  Baseline FEV1 80-120% of predicted at Screening.

          -  Oxygen saturation of ≥ 96% on room air as determined by pulse oximetry at Screening.

          -  Screening laboratory tests within normal limits.

        Part B

          -  Female and Male subjects who are ≥18 years of age and a confirmed diagnosis of CF.

          -  FEV1 >50% of predicted.

          -  Oxygen saturation of ≥ 94% on room air as determined by pulse oximetry at Screening.

          -  Stable CF pulmonary disease as judged by the Investigator.

        Exclusion Criteria:

        Part A

          -  Any history of any form of lung disease or any systemic disease that may affect the
             lung or pulmonary function.

          -  Former regular smoker or has smoked tobacco or cannabis products within the last 30
             days.

          -  Any history of any form of liver disease, renal disease, cardiac disease, hematologic
             disease, neurologic disease, atopy or any chronic condition.

          -  Participation in one or more healthy subject studies within the prior 3 months.

        Part B

          -  Participation in a clinical trial involving receipt of an investigational product
             within the 30 days prior to screening.

          -  Female subjects who are pregnant (a negative serum pregnancy test must be demonstrated
             at screening), have a positive pregnancy test, are lactating or who plan to become
             pregnant within 90 days after dosing.

          -  Subjects requiring supplemental oxygen.

          -  Hemoptysis of >5 mL within 12 weeks of screening.

          -  Listed for organ transplantation.
Clinical trial NCT03339453 (phase 1, status: completed)
Conditions: hypoglycemia, diabetes mellitus, type 1
ICD codes: E16.1, E16.2, P70.3, P70.4, E16.0, E10.641, E10.649, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: nasal glucagon, intramuscular glucagon
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Type 1 Diabetes Mellitus (T1DM) for at least 2 years and receiving daily
             insulin since the time of diagnosis

        Exclusion Criteria:

          -  Have a history of hypersensitivity to glucagon or any related products or severe
             hypersensitivity reactions (such as angioedema) to any drugs

          -  Have a history of pheochromocytoma (that is, adrenal gland tumor) or insulinoma

          -  Occurrence of an episode of severe hypoglycemia (defined as requiring the assistance
             of another person in the 1 month prior to enrolling in the study)

          -  Have a history of epilepsy or seizure disorder

          -  Are women who are pregnant or lactating

          -  Have, except for the current regimen of insulin therapy and concomitant medication,
             regular use of or intended use of any over-the-counter or prescription medications or
             nutritional supplements that treat hyperglycemia or insulin resistance or that promote
             weight loss within 14 days before dosing

          -  Daily use of systemic beta-blocker, indomethacin, warfarin or anticholinergic drugs

          -  Require daily insulin treatment greater than (>)1.5 unit/kilograms (U/kg)/body weight
Clinical trial NCT03343652 (phase 1/phase 2, status: completed)
Conditions: hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: nivolumab, bendamustine hydrochloride
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis: Histologically confirmed Hodgkin's lymphoma

          -  Relapsed or refractory to at least two prior treatment lines

          -  Relapsed after nivolumab treatment or refractory to nivolumab treatment

          -  Age 18-70 years old

          -  Signed informed consent

          -  No severe concurrent illness

        Exclusion Criteria:

          -  Uncontrolled bacterial or fungal infection at the time of enrollment

          -  Requirement for vasopressor support at the time of enrollment

          -  Karnofsky index <30%

          -  Pregnancy

          -  Somatic or psychiatric disorder making the patient unable to sign informed consent

          -  Active or prior documented autoimmune disease requiring systemic treatment.
Clinical trial NCT03383692 (phase 1, status: active, not recruiting)
Conditions: neoplasm metastasis
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: ds-8201a, ritonavir, itraconazole
SMILES: CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          -  Has a pathologically documented unresectable or metastatic solid malignant tumor, with
             HER2 expression [immunohistochemistry (IHC) 3+, 2+, or 1+ and/or in situ hybridization
             (ISH) +], Next Generation Sequencing, or other analysis techniques as appropriate]
             that is refractory to or intolerable with at least one prior systemic chemotherapy
             regimen, or for which no standard treatment is available

          -  Has a left ventricular ejection fraction (LVEF) ≥ 50%

          -  Has an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1

        Exclusion Criteria:

          -  Has a contraindication for receiving ritonavir or itraconazole according to the
             prescribing information

          -  Has a medical history of myocardial infarction within 6 months before enrollment or
             symptomatic congestive heart failure
Clinical trial NCT03411421 (phase 1, status: terminated)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: al-794, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the study was closed as the data received to date did not support continuation of the study.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Participant has provided written informed consent

          -  In the Investigator's opinion, the participant is able to understand and comply with
             protocol requirements, instructions, and protocol-stated restrictions and is likely to
             complete the study as planned

          -  Participant is deemed healthy on the basis of physical examination, medical history,
             vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests performed
             at screening

          -  Body mass index (BMI) 18 - 32 kilogram per meter square (kg/m^2), inclusive. The
             minimum weight is 50 kilogram (kg). No more than 25 percent (%) of participants may be
             enrolled with a BMI greater than or equal to (>=) 30 kg/m^2

          -  Female participants must have a negative serum (beta-human chorionic gonadotropin
             [beta-hCG]) pregnancy test at screening and on Day -1 (admission)

        Exclusion Criteria:

          -  Female who is pregnant as confirmed by a positive beta-human chorionic gonadotropin
             (beta-hCG) laboratory test, or who was pregnant within 6 months prior to study start,
             or who is breast-feeding, or who is planning to become pregnant from signing of the
             informed consent form (ICF) until 90 days after the last dose of study drug

          -  Male whose female partner is pregnant or contemplating pregnancy from the date of
             screening until 90 days after their last dose of study drug

          -  Participant with one or more of the following laboratory abnormalities at screening:
             aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 1.2*upper limit
             of normal (ULN); Alkaline phosphatase (ALP) >= 1.2*ULN; Total bilirubin >= 1.2*ULN;
             Clinically significant laboratory abnormalities or abnormalities which are deemed to
             interfere with the ability to interpret study data

          -  Creatinine clearance less than (<) 90 milliliter per minute (mL/min) (using the
             Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation)

          -  Positive screening test for human immunodeficiency virus type 1 (HIV-1) or HIV-2
             antibody, or for current hepatitis A infection (confirmed by hepatitis A antibody
             immunoglobulin M [IgM]), or hepatitis B virus (HBV) infection (confirmed by hepatitis
             B surface antigen [HBsAg]), or hepatitis C virus (HCV) infection (confirmed by HCV
             antibody) at screening
Clinical trial NCT03431610 (phase 1, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: sb414 2%, sb414 6%, vehicle
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, 18 years of age and older, and in good general health;

          -  EASI score >1 and ≤21, involving ≥5% body surface area (BSA).

          -  Two target lesions at least 5 cm2 with a TLSS ≥5. Target lesions can not be located on
             the groin, hands, elbows, feet, ankles, knees, face or scalp.

          -  Willing to not use any other products for AD during the study;

          -  Women of childbearing potential (WOCBP) must have a negative urine pregnancy test
             (UPT) prior to randomization and must agree to use an effective method of birth
             control during the study and for 30 days after their final study visit.

        Exclusion Criteria:

          -  Concurrent or recent use of topical or systemic medications without a sufficient
             washout period;

          -  Immunocompromised subjects including those who are known HIV positive or receiving
             current immunosuppressive treatment,

          -  Female subjects who are pregnant, nursing mothers, or planning to become pregnant
             during the study;

          -  Active acute bacterial, fungal, or viral skin infection within 1 week before the
             baseline visit.
Clinical trial NCT03445013 (phase 1, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: sb414 6%, vehicle
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Be male or female, 18-70 years old, and in good general health;

          -  Have a clinical diagnosis of stable chronic plaque psoriasis of mild to moderate
             severity based on the PSGA, involving 2-15% BSA (excluding the scalp/face), present
             for > 6 months;

          -  Must have at least 2 target plaques on trunk and/or extremities at least 5 cm2 with a
             TPSS > 5 and thickness sub-score > 2. Target plaques cannot be located on the groin,
             hands, feet, neck, face, elbows, knees, ankles or scalp;

          -  Be willing to not use any other systemic agents used to treat psoriasis or apply any
             other topical products (medicated or over-the-counter) to the treatment sites on the
             trunk and/or extremities during the study;

          -  Women of childbearing potential (WOCBP) must have a negative UPT prior to
             randomization and must agree to use an effective method of birth control during the
             study and for 30 days after their final study visit.

        Exclusion Criteria:

          -  Have inverse (i.e.: axillae, groin) or facial psoriasis only, erythrodermic psoriasis,
             guttate psoriasis, pustular psoriasis, drug-induced psoriasis, and /or psoriatic
             arthritis requiring treatment with disease modifying antirheumatic drugs (DMARDs);

          -  Concurrent or recent use of topical or systemic medications without a sufficient
             washout period;

          -  Are immunocompromised, including those who are known HIV positive or received
             immunosuppressive treatment within the past 6 months;

          -  Female subjects who are pregnant, nursing mothers, or planning to become pregnant
             during the study.
Clinical trial NCT03500783 (phase 1/phase 2, status: completed)
Conditions: coronary artery disease, coronary artery bypass, cardiopulmonary bypass, nitric oxide, reperfusion injury, myocardial
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118, T82.212S, T82.213S, T82.211S, T82.212A, T82.212D, T82.213A, T82.213D, Q93.81, B33.4, A36.81, A50.54, A52.00, A52.09, B33.24
Drugs: nitric oxide
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1NC=NC2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Coronary artery disease requiring coronary artery bypass grafting with the
             cardiopulmonary bypass.

        Exclusion Criteria:

          -  Non-elective surgery, age over 70 years, left ventricular ejection fraction less than
             35%, history of myocardial infarction within three months prior to surgery, chronic
             atrial fibrillation, diabetes mellitus, and the elevated levels of cardiac specific
             markers within 12 h prior to the intervention.
Clinical trial NCT03508687 (phase 1/phase 2, status: completed)
Conditions: familial partial lipodystrophy, hypertriglyceridemia, fatty liver, nash - nonalcoholic steatohepatitis
ICD codes: E88.1, K70.0, K76.0, K75.81
Drugs: 300mg gemcabene, 600mg gemcabene
SMILES: CC(C)(CCCCOCCCCC(C)(C)C(O)=O)C(O)=O, CC(C)(CCCCOCCCCC(C)(C)C(O)=O)C(O)=O
Eligibility criteria:

        -  Clinical diagnosis of lipodystrophy based on a lack of body fat in a partial fashion
             assessed by physical examination, and at least 1 MAJOR criterion (below):

          -  Low skinfold thickness in anterior thigh by caliper measurement: men (≤ 10 mm) and
             women (≤ 22 mm) OR

          -  Historic genetic diagnosis of familial partial lipodystrophy (e.g. mutations in LMNA,
             PPAR-γ, AKT2, or PLIN1 genes) as supported by source documentation

          -  Hepatic steatosis (>10% - Stage 2 or 3) as demonstrated by MRI-PDFF;

          -  Alcohol intake of less than 20 g per day in females and 30 g per day in males (one 12
             oz beer, one glass of wine, or 2 oz of spirits or liquor equals roughly 10 g of
             alcohol;

          -  Mean fasting triglyceride value ≥ 250 mg/dL at the Screening Visit;

          -  Background lipid lowering medications must be stable for at least 6 weeks prior to the
             Screening Visit;

          -  Women patients must not be pregnant or lactating and women of child-bearing potential
             must agree to use acceptable methods of contraception throughout the duration of the
             study and for 30 days after the last dose of study drug. Male patients must agree to
             use contraception by means of a condom and may not donate sperm throughout the
             duration of the study and for 8 days after the last dose of study drug.

          -  Weight greater than 50 kg (~110 lbs); with a body mass index (BMI) of no more than 45
             kg/m²;

          -  Have not used a fibrate with in the last 6 weeks and/or thiazolidinediones (TZDs)
             within the last 12 weeks prior to the Screening visit.

          -  Do not have a hypersensitivity or a history of significant reactions of fibrates.

          -  Are not currently taking potent CYP3A4 inhibitors such as itraconazole or a macrolide
             antibiotic.

          -  Have a condition or finding which, in the opinion of the Investigator, would
             compromise the patient's safety or participation in the study.